Condition
Scorpion Sting Envenomation
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 3 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01599923Phase 3CompletedPrimary
Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
NCT00685230Phase 2CompletedPrimary
Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients
NCT00624078Phase 2CompletedPrimary
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
NCT00696683CompletedPrimary
Establishment of Natural History of Scorpion Envenomation
Showing all 4 trials